AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Achiko AG

Earnings Release Aug 31, 2022

804_rns_2022-08-31_70015584-6eb8-47b1-b687-14d7a1892f36.html

Earnings Release

Open in Viewer

Opens in native device viewer

Ad hoc announcement pursuant to Art. 53 LR

Achiko AG / Key word(s): Annual Results

Achiko AG Announces Newly Published Annual Report and Accounts for the Year Ended 31 December 2021

31-Aug-2022 / 23:55 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Achiko AG Announces Newly Published Annual Report and Accounts for the Year Ended 31 December 2021

Zurich, 31 August 2022: Ad hoc an n o u ncement pu r su a nt to Art. 53 LR –  Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended 31 December 2021.

On 9 August 2022, the Company announced that Achiko will publish its 2021 annual report on 31 August 2022 at the latest. Achiko has published its 2021 annual financial statements on 26 June 2022. With a decision dated 27 June 2022, SIX Exchange Regulation (“SER”) concluded that the annual financial statements published on 26 June 2022 do not comply with Art. 49 and 51 of the Listing Rules of SIX Swiss Exchange (“LR”) and suspended trading of Achiko’s shares based on Art. 57 LR as of 28 June 2022 until the orderly conditions are restored. In addition, Achiko was given a deadline until 31 July 2022 to publish audited financial statements in accordance with Art. 49 and 51 LR. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 7 August 2022, SER granted Achiko the requested extension until 31 August 2022. On 9 August 2022 Achiko noted it has conferred with its existing significant shareholders and is working to ensure compliance with Art. 49 and 51 LR. 

With the support of its significant shareholders, creditors and staff, the Company is now pleased to publish its 2021 annual financial statements that comply with Art. 49 and 51 LR.  Of material note is the Company entering into USD 1,250,000 in convertible notes, exercisable at CHF 0.059, of which USD 275,000 was provided as a bridge, and the conversion of various trade creditors, staff and all save one of the Directors and Advisory Board members past and present of their claims to being subordinated for the purposes of Art. 725 para. 2 of the Swiss CO to an additional USD 806,106 over and above the amount reported at 31 December 2021.

For the year ended 31 December 2021, the Group recorded a net loss of USD 9,231,779 resulting in an increase of the Group’s accumulated losses to USD 34,568,395.   The Company notes that the financial results are unchanged, but the newly published Annual Report replaces the previously published Annual Report in its entirety.

The Annual Report is available for download at:  https://www.achiko.com/financials/ .

The Annual General Meeting of shareholders will take place in late September or early October 2022 on a date to be announced in due course.

ABOUT ACHIKO A G  

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF;  www.achiko.com ) is developing disruptive diagnostic solutions that puts people first. The Company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE Mark in the European Union in May 2022.  

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX TM and companion health apps via its digital mobile health technology division, Teman Sehat TM . The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

M edia contacts:   

ACHIKO AG

Investor Relations

E: [email protected]

Switzerland & Global

Marcus Balogh

Farner Consulting Ltd

E: [email protected]

T: +41 44 266 67 67

Disclaimer  

This communi c a tio n expressl y or i m plicitly c o nta i ns certa i n f or w ard-look i ng s tatem e nts c o ncernin g A chik o A G an d it s business . Suc h stat e ment s in v olv e certai n k n o w n a n d un k no w n risks, uncer t ainties a n d othe r f actors, w hi c h coul d cause the actua l results, f i n ancial c o nditi o n, per f or m ance or achi e vement s o f A chik o A G to be material l y di ff erent f rom any f u t ure results, pe r f ormance or achiev e ments expressed or implie d by such f or w ard-l o oki n g statem e nts. A chiko A G is providing this com m uni c ati o n as o f this date and d oe s not u nder t ake to u p d ate a n y f or w ard- l ooki n g stat e ments contain e d herein as a result o f ne w in f ormat i on , future eve n ts or o ther w ise


End of ad hoc announcement


Language: English
Company: Achiko AG
Tessinerplatz 7
8002 Zurich
Switzerland
E-mail: [email protected]
Internet: https://www.achiko.com/
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1432827
End of Announcement EQS News Service

1432827  31-Aug-2022 CET/CEST

Talk to a Data Expert

Have a question? We'll get back to you promptly.